Scientific Advisory Board

Lee E.  Babiss, Ph.D., was until recently Head, Global Pharma Research, Hoffmann-La Roche Ltd. Dr. Babiss led and managed research within Roche Pharma’s five Disease Biology Areas. He also served as a member of the Pharma Executive and the Strategic Portfolio Committee. Dr. Babiss was vice president of Biological Sciences and Genetics at Glaxo Wellcome and a member of the U.S. Research Senior Management Team.  He was also involved in creating the Glaxo Wellcome Corporate Genetic Strategy.  Dr. Babiss earned his Ph.D. in Microbiology at Columbia University, College of Physicians and Surgeons and did postdoctoral work at the Rockefeller University in New York.

Brian Kay, Ph.D., is Professor and Head of the Department of Biological Sciences at University of Illinois, Chicago. His interest is in functional genomics using various display technologies.  He is an international expert in phage display.  Dr. Kay received his undergraduate and graduate training at the University of Chicago and Yale University, respectively, and then did post-doctoral training at NIH. Prior to joining UIC, he was an Assistant and Associate Professor at UNC-CH, Professor at University of Wisconsin-Madison, and Staff Scientist at Argonne National Laboratory. He has authored more than 110 publications and reviews, co-edited a number of books, and been issued more than 15 patents. 

Ulf Landegren, M.D., Ph.D., is Professor of Molecular Medicine at Uppsala University (Uppsala, Sweden), the university where he originally studied medicine and obtained his Ph.D. in cellular immunology. He then joined the California Institute of Technology (Caltech) (Pasadena, USA) where he carried out postdoctoral research. In 1989 he returned to Uppsala University and in recent years his work has increasingly focused on the development of techniques for protein detection and his group has developed the proximity ligation assay for sensitive and specific DNA-assisted protein analyses. He is a member of EMBO and of the Royal Swedish Academy of Sciences. Professor Landegren sits on several scientific advisory and journal editorial boards.

Michael Snyder, Ph.D., a co-founder of Affomix, is Chair, Department of Genetics and Director, Center for Genomics and Personalized Medicine at Stanford University. Dr. Snyder’s laboratory built the first proteome chip for any organism and the first high resolution tiling array for the entire human genome. Dr. Snyder has more than 250 publications and he is editor of a number of journals. He is recipient of the Connecticut Medal of Science. He sits on many international advisory boards and was a cofounder of Protometrix, Inc., a protein microarray company that was purchased by Invitrogen in 2004. Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral work at Stanford University. 

Mathias Uhlen, Ph.D. is Professor of Microbiology at the Royal Institute of Technology, Stockholm, Sweden. Dr Uhlen is member of the Royal Swedish Academy of Engineering Science, the Royal Swedish Academy of Science and the European Molecular Biology Organization. He is Vice-President of the European Proteomics Association and member of the Human Proteome Organization council. He was formerly Vice-President of the Royal Institute of Technology and chairman of the Swedish Biochemical and Molecular Biology Society. Dr Uhlen has more than 280 bioscience publications. Dr Uhlen has founded several companies and has received numerous awards, including the gold medal of the Royal Swedish Academy of Engineering Sciences, the Jerker Porath award and the Akzo Nobel Award.

Sherman Weissman, MD., a co-founder of Affomix, is Sterling Professor of Genetics, Director, Molecular Oncology&Development, Boyer Center for Molecular Medicine and a member of the National Academy of Science. He has published over 300 original scientific papers and edited several technical books. His recent work includes the purification of multi-protein complexes, investigation of the utility of RNA for cell transfection and ongoing work on the immunologic functions of the major histocompatibility complex. In addition to his academic accomplishments, Dr. Weissman has either co-founded or participated in early developmental stages of five biotechnology companies. Three of these are now publicly traded companies while the other two were purchased by larger firms.

David Weitz, Ph.D. is Mallinckrodt Professor of Physics and Applied Physics at Harvard University, where he has a joint appointment in the Department of Physics and the School of Engineering and Applied Sciences. He is also the director of Harvard's Materials Research Science and Engineering Center.  He leads an experimental group investigating the properties of soft materials and exploring ways that microfluidcs can be used for studies of soft materials.  Dr Weitz received his PhD from Harvard.  Before joining the Harvard faculty, Dr. Weitz spent several years at Exxon Research and Engineering as a research physicist and was Professor of Physics at the University of Pennsylvania. He is involved in several start-up companies based on research done in his lab.